Home/Filings/4/0001193125-26-006350
4//SEC Filing

Cabell Christopher 4

Accession 0001193125-26-006350

CIK 0001750149other

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 4:21 PM ET

Size

5.3 KB

Accession

0001193125-26-006350

Insider Transaction Report

Form 4
Period: 2026-01-05
Cabell Christopher
President & Head of R&D
Transactions
  • Award

    Stock Option (Right to Buy)

    2026-01-05+900,117900,117 total
    Exercise: $2.01Exp: 2036-01-05Common Stock (900,117 underlying)
Footnotes (1)
  • [F1]The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

Documents

1 file

Issuer

Inhibikase Therapeutics, Inc.

CIK 0001750149

Entity typeother

Related Parties

1
  • filerCIK 0001814928

Filing Metadata

Form type
4
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 4:21 PM ET
Size
5.3 KB